The Angeles Clinic and Research Institute

Summary

The Angeles Clinic and Research Institute is a medical facility located in Los Angeles, California. This center is recognized for care of Melanoma, Cancer, Solid Tumors, Pancreatic Cancer, Lung Cancer and other specialties. The Angeles Clinic and Research Institute is involved with conducting 111 clinical trials across 114 conditions. There are 9 research doctors associated with this hospital, such as Omid Hamid, Navid Hafez, MD, Inderjit Mehmi, MD, and Vi K Chiu.

Top PIs

Clinical Trials running at The Angeles Clinic and Research Institute

Skin Cancer

Cancer

Melanoma

Lung Cancer

Ovarian Cancer

Solid Tumors

Breast Cancer

Endometrial Cancer

Cutaneous Melanoma

Pancreatic Cancer

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

VO + Nivolumab

for Advanced Melanoma

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.

Recruiting

2 awards

Phase 3

3 criteria

Biomarker-Guided Immunotherapy Discontinuation

for Melanoma

This trial uses drugs that boost the immune system to fight advanced melanoma that can't be surgically removed. It aims to see if doctors can safely shorten the treatment period by using imaging tests to guide decisions. Pembrolizumab and ipilimumab are immunotherapy drugs used to treat advanced melanoma, with pembrolizumab approved for younger patients and ipilimumab showing positive results in previous studies.

Recruiting

1 award

Phase 2

22 criteria